Clinical trials: Glioblastoma Multiforme (GBM)
Recurrent Glioblastoma IDH Wildtype
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with resected recurrent glioblastoma (rGBM) via convection enhanced…
- Trial name
- NCT06455605
- Testing
- D2C7-IT, 2141 V11
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Darell Bigner
Brain and Central Nervous System Tumors
Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme
RATIONALE: Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells.
- Trial name
- NCT00915694
- Testing
- nelfinavir mesylate, temozolomide, adjuvant therapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
This clinical trial is designed with two treatment stages: Stage 1: one cycle of study drug treatment prior to initiation of first-line standard radiation in all study participants.
- Trial name
- NCT07778602
- Testing
- avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma of Cerebellum
DLL3 CAR-T Therapy Targeting Brain Tumors
The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic…
- Trial name
- NCT07180927
- Testing
- 4SCAR DLL3 T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Glioblastoma Multiforme of Brain, Brain Cancer
The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors
Glioblastoma patients are confronted with a debilitating disease associated with a low survival rate and poor quality of life. The goal of this study will be to reach a largely underrepresented population in the exercise…
- Trial name
- RESIST (NCT05116137)
- Testing
- Circuit-based resistance exercise (CRT)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Nova Scotia Health Authority
Glioblastoma Multiforme, Glioblastoma, Adult
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
Monocentric randomized phase I/II trial, including 24 patients diagnosed with relapsing glioblastoma (GBM) irrespective of MGMT and IDH gene status.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Adult, Glioma of Brain, Glioblastoma Multiforme of Brain
- Trial name
- IMA950-106 (NCT03665545)
- Testing
- IMA950/Poly-ICLC, IMA950/Poly-ICLC and pembrolizumab
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Geneva
Brain and Central Nervous System Tumors
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005951
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- United States
- Sponsor
- Duke University
Glioblastoma
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at…
- Trial name
- GLIOSTELLA (NCT06336291)
- Testing
- L19TNF, Lomustine
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Philogen S.p.A.
Anaplastic Glioma of Brain, Glioblastoma Multiforme
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
The goal of this clinical research study is to learn if the combination of 6-Thioguanine, Xeloda (capecitabine), and Celebrex (celecoxib) with Temodar (temozolomide) or Lomustine (CCNU) is effective in the treatment of recurrent…
- Conditions
- Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer
- Trial name
- NCT00504660
- Testing
- Capecitabine, Celecoxib (Celebrex), Temozolomide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
Prognosis and Therapeutic Biomarkers for Glioblastoma Patients
The purpose of this study is to investigate if the potential biomarkers identified could be used for facilitating the diagnosis and prognosis of patients with glioblastoma (GBM).
- Trial name
- NCT03403803
- Testing
- Optune
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Glioblastoma
Glioblastoma Evaluation for Heterogeneity In RadioseNsitivity
This is an observational study on GBM surgical samples to investigate if increasing doses of radiation therapy could improve the radiation response; and in particular the investigators will assess if there is a correlation…
- Trial name
- GEHIRN (NCT05556382)
- Testing
- radiation of brain tissue specimen and dna damage analysis
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Istituto Clinico Humanitas
GBM
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
This study is designed with open-label and randomized parallel group to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an add-on treatment for primary glioblastoma multiforme
- Trial name
- NCT04115761
- Testing
- autologous dendritic cells
- Where
- 3 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Glioblastoma
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly…
- Trial name
- NCT05187624
- Testing
- RO7428731
- Where
- 8 sites in United States, Australia and 3 more
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
High Grade Glioma, Glioblastoma
Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
The goal of this clinical trial is to: 1) evaluate the safety, tolerability, and recommended dose of dexbrompheniramine when combined with metronomic temozolomide for adults with recurrent high-grade glioma who have been…
- Conditions
- High Grade Glioma, Glioblastoma, Gliosarcoma
- Trial name
- NCT07859059
- Testing
- Dexbrompheniramine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Nebraska
Glioblastoma Multiforme
Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
The purpose of this study is to find out whether Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) combining with temozolomide chemotherapy can be safely given with a targeted agent, bevacizumab, and how…
- Trial name
- NCT01209442
- Testing
- Bevacizumab, Temozolomide, RT (Radiation Therapy)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Colorado, Denver
Glioblastoma Multiform (Grade IV Astrocytoma)
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
In order to test the investigators hypothesis that 8 teaspoons of POLYMVA is safe in a population of patients with grade IV brain astrocytoma (glioblastoma multiforme), the investigators will conduct an open-label, prospective…
- Trial name
- DESSTINI_A (NCT01833273)
- Testing
- PolyMVA
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stony Brook University
Glioblastoma
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
A one time oral dose of ALA is taken before surgery. The medication makes the tumor visible under ultraviolet light which allow the surgeon to see more of the tumor for a more complete removal.
- Trial name
- NCT00961090
- Testing
- Aminolevulinic Acid
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Matthew R Quigley
High Grade Gliomas, Brain Tumors
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
Background: Radiation therapy with temozolomide (an anti-cancer drug) is standard therapy for treating brain tumors called glioblastomas.
- Trial name
- NCT00302159
- Testing
- adjuvant therapy, Temozolomide, Valproic Acid
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Astrocytoma, Grade IV
The Addition of Chloroquine to Chemoradiation for Glioblastoma,
Glioblastomas (GBM) are the most common type of primary brain tumors with an annual incidence of approximately 500 patients in the Netherlands.
- Trial name
- NCT02432417
- Testing
- Chloroquine
- Sponsor
- Maastricht Radiation Oncology
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University